Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COLUMN
Maurer's Healthcare Insight (86)
Japan Is Not (Is) an Attractive MarketPart 1P. Reed MaurerAt a recent conference in Tokyo I was asked to give a pessimistic perspective of the Japanese healthcare market. I would like to share my presentation with the readers of PHARMA…
To read the full story
COLUMN
- The One Mistake on Your Resume
August 31, 2026
- Why Your Brain Wants You to Stay (Even When You Want to Go)
July 31, 2026
- The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard
June 26, 2026
- More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry
May 29, 2026
- The Patient North Star: How Gilead Japan Redefined Innovation
April 8, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…